|
Aug 6
|
Tetraspecific Antibodies Market Research 2025-2029 | Molecular Partners, Innate Pharma, and ModeX Therapeutics Lead Innovations for Oncology and Autoimmune
|
|
Apr 16
|
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
|
|
Dec 22
|
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%
|
|
Dec 10
|
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
|